Ovarian Cancer Trial, Recruiting (NCT06324175)

Ovarian Cancer Trial, Recruiting NCT06324175 Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Condition: Ovarian Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06324175 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ovarian Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People with suspected high-grade serous ovarian cancer (a specific type of ovarian cancer) who are scheduled for surgery to remove as much of the cancer as possible, either before or after chemotherapy.
For those scheduled for surgery after chemotherapy, a previous tissue biopsy confirming the cancer type is required before joining.
For those scheduled for surgery before chemotherapy, selection may be based on a blood test result (CA125) and CT scan findings, without a prior biopsy (confirm with trial site).

Who may not be able to join:

People under 18 years of age.
People who are pregnant.
People whose ovarian cancer is a different type, such as low-grade serous, mucinous, clear cell, endometrioid, or a non-epithelial ovarian cancer.
People whose cancer is at an early stage (Stage I or Stage II).
People who do not have a CT scan or MRI scan available.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 14 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Camilla Panico, Dr, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phone: +390630158637

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06324175

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase: Not Applicable

Status: Recruiting

Condition: Ovarian Cancer

Trial contact: +390630158637

More information: https://clinicaltrials.gov/study/NCT06324175

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People with suspected high-grade serous ovarian cancer (a specific type of ovarian cancer) who are scheduled for surgery to remove as much of the cancer as possible, either before or after chemotherapy.
For those scheduled for surgery after chemotherapy, a previous tissue biopsy confirming the cancer type is required before joining.
For those scheduled for surgery before chemotherapy, selection may be based on a blood test result (CA125) and CT scan findings, without a prior biopsy (confirm with trial site).

Who may not be able to join:

People under 18 years of age.
People who are pregnant.
People whose ovarian cancer is a different type, such as low-grade serous, mucinous, clear cell, endometrioid, or a non-epithelial ovarian cancer.
People whose cancer is at an early stage (Stage I or Stage II).
People who do not have a CT scan or MRI scan available.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Registry

ClinicalTrials.gov

Start date

1 February 2024

Est. completion

31 December 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Implementation of the 3D printing pipeline in the clinical setting for recurrent HGSOC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov